Acetylcholinesterase (blood, hippocampus, frontal cortex, basal ganglia, septum and diaphragm) or butyrylcholinesterase (liver) activities following i.m. administration of tacrine (9-amino-1,2,3,4-tetrahydroacridine), its 7-methoxy- and 7-hydroxy derivatives to rats in dose of 1.2 x LD50 were detected. The most marked inhibition of the enzymes studied following tacrine administration was demonstrated in the frontal cortex, diaphragm, liver and blood. Inhibition of acetylcholinesterase in the frontal cortex and blood only was observed following administration of tacrine derivatives. The results indicate that inhibition of cholinesterases could be important but not unique part explaining the action of these drugs in general.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Effect of Tacrine on Functional Response of the Lower Oesophageal Sphincter Assessed by Endoscopic Luminal Impedance Planimetry in Experimental Pigs.
Pharmaceuticals (Basel)
November 2024
Biomedical Research Centre, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic.
Tacrine is a centrally active non-competitive reversible acetylcholinesterase inhibitor. It also exerts antagonising activity against -methyl-D-aspartate receptors. Tacrine was approved for the treatment of Alzheimer's disease in 1993, but was withdrawn from clinical use in 2013 because of its hepatotoxicity and gastrointestinal side effects.
View Article and Find Full Text PDFExploring the diverse acetylcholinesterase inhibitory potential of girinimbine: insights from in vitro assays, molecular docking, and simulation studies.
Cell Mol Biol (Noisy-le-grand)
November 2024
Health Research Center, Jazan University, P.O. Box: 114, Jazan 45142, Saudi Arabia.
The search for new treatments for Alzheimer's disease (AD) has led to the exploration of plant-based drugs as potential options. Acetylcholinesterase (AChE) inhibitors are widely used as anti-AD medications. This study aimed to investigate the inhibitory mechanism of girinimbine, a constituent of Murraya koenigii, on AChE.
View Article and Find Full Text PDFApplying Spatial Metabolomics To Investigate Age- and Drug-Induced Neurochemical Changes.
ACS Chem Neurosci
August 2024
Department of Pharmaceutical Biosciences, Spatial Mass Spectrometry, Science for Life Laboratory, Uppsala University, Uppsala SE-75124, Sweden.
Article Synopsis
- The study investigates the effects of aging on neurochemical changes in the mouse brain using advanced analytical techniques, focusing on lipid alterations and metabolic mapping.
- It finds significant age-related changes in brain lipids, particularly in sulfatides and lysophosphatidic acids, demonstrating the complexity of neurochemical signaling as the brain ages.
- The research also reveals that administration of the acetylcholinesterase inhibitor tacrine leads to notable shifts in the glutamine/glutamate ratio, indicating potential neurotoxicity and glial-neuron interaction changes due to aging.
Protective Effects of Red Ginseng Against Tacrine-Induced Hepatotoxicity: An Integrated Approach with Network Pharmacology and Experimental Validation.
Drug Des Devel Ther
March 2024
Department of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
Introduction: Tacrine, an FDA-approved acetylcholinesterase inhibitor, has shown efficacy in treating Alzheimer's disease, but its clinical use is limited by hepatotoxicity. This study investigates the protective effects of red ginseng against tacrine-induced hepatotoxicity, focusing on oxidative stress.
Methods: A network depicting the interaction between compounds and targets was constructed for RG.
Research and progress of focused ultrasound in the treatment of Alzheimer's disease.
Front Neurol
December 2023
Department of Ultrasound, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
Article Synopsis
- Alzheimer's disease is a common degenerative condition that leads to serious cognitive and memory decline, affecting around 46 million people globally, with predictions of this number tripling by 2050, creating significant healthcare challenges.
- * The FDA has approved five main drugs for treating Alzheimer's, but their effectiveness is limited due to the blood-brain barrier.
- * Recent advancements in focused ultrasound technology show promise for non-invasive treatment by targeting deep brain areas and improving drug delivery, offering new hope in Alzheimer's research.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!